This section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Article content
GHENT, Belgium & TOKYO — H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil.
Sign In or Create an Account
or View more offersArticle content“ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.”Article contentWe apologize, but this video has failed to load.Try refreshing your browser, or
tap here to see other videos from our team.Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two assays, reflecting conformity with the safety and performance requirements of the different regulatory agencies. The assays were also granted Class II Medical Device Licenses (MDL) by Health Canada earlier this month. Together, these milestones broaden access to Fujirebio’s high-quality biomarker solutions and strengthen its comprehensive neurological diagnostics portfolio. Through its expanding menu of blood-based and cerebrospinal fluid (CSF) biomarkers, Fujirebio aims to contribute to a timelier diagnosis, more informed treatment decisions and improved patient care in neurological disease.
Article contentArticle contentAbout Lumipulse G NfL BloodArticle content
The Lumipulse G NfL Blood assay is intended for the quantitative measurement of neurofilament light chain (NfL) in human serum and plasma.
Article content
NfL is a well-established biomarker of neuro-axonal injury and has been studied across a wide range of neurological conditions, including for its potential utility in disease monitoring, prognosis, and assessment of treatment response. This broad applicability underscores the value of linking the biomarker to the pathophysiology it represents rather than to a disease.
Article content
Results from the Lumipulse G NfL Blood assay should be interpreted in the clinical context and with appropriate reference values and validated clinical decision frameworks.
Article contentAbout Lumipulse G pTau 217 PlasmaArticle content
Tau phosphorylated at threonine 217 (pTau 217) is a highly specific blood-based biomarker associated with Alzheimer’s disease (AD) pathology. It can support the assessment of underlying amyloid pathology and help clinicians distinguish AD from other causes of cognitive decline.
Article content
The Lumipulse G pTau 217 Plasma assay is intended to aid healthcare providers in identifying amyloid pathology associated with AD in individuals aged 50 years and older who present themselves with signs and symptoms of cognitive decline in specialized care settings. The assay is to be used as an adjunct to other diagnostic evaluations.
Article contentAbout FujirebioArticle content
Fujirebio is a diagnostics company with over 75 years of experience delivering innovative solutions to healthcare providers, pharmaceutical companies, and IVD partners worldwide. Leveraging world-class expertise in neurology, oncology, infectious diseases, and beyond, and assays available on the robust LUMIPULSE® G platform, Fujirebio’s open business model accelerates access to breakthrough diagnostics through strategic partnerships across the life science industry.
Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
Part of H.U. Group, Fujirebio combines strong R&D capabilities, regulatory expertise, and scalable manufacturing to deliver high-impact diagnostic solutions. Fujirebio’s flexible CDMO model helps its diagnostic partners bring validated solutions to the market faster, driving better decisions, treatments, and patient outcomes.
Article content
For more information, please visit www.fujirebio.com Lumipulse is a registered trademark of Fujirebio Inc.
Article contentArticle contentArticle contentArticle contentView source version on businesswire.com: Article content
https://www.businesswire.com/news/home/20260913014027/en/
Article contentArticle content
Contacts
Article content
For media:
Public Relations Section, Public Relations/Sustainability Department,
H.U. Group Holdings, Inc.
Phone: +81-3-6279-0884
E-mail: [email protected] Christiaan De Wilde
CEO Fujirebio Europe
Phone: +32 9329 1703
Article content